NASDAQHealth CareMedical - Healthcare Information ServicesSnapshot 2026-08-31
Reading HTFL? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Health Care is in expansion. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisRanks in the weakest quality tier of its industry — roughly the bottom 43%, softest on share dilution.
View QualityMiddle-of-the-pack management execution.
View ManagementExpectations look high — the market is pricing in about 44% growth a year, above the roughly 33% analysts expect, leaving little room for error.
View ValuationThis stock is volatile — it swings about 2% on a typical day and fell roughly 49% in its worst 12-month stretch.
View RiskHTFL's growth depends on its ability to raise revenue guidance. Recent performance shows revenue surged 48% year over year. The company beat earnings estimates and raised its annual revenue guidance to $246 million to $250 million. HTFL trades at 19 times sales, while peers trade at 2 times sales. This suggests the price reflects less growth than expected. If HTFL cuts guidance after a recent raise, it risks credibility. Peer multiples imply a price about 37% below where it trades. Our read is provisional.
Trailing returns as of 2026-08-31. HTFL is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 9 analysts currently covering HTFL (as of Aug 2026).
Based on 6 Wall Street analysts offering 12-month price targets for HTFL in the last 4 months.
A consensus fair price across 3 valuation methods, at three horizons. As of 2026-08-31. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Health Care Technology — fair value, gap to price, and forward P/E.
Threatens: Increase annual revenue guidance to $246M-$250M
Q2 EPS miss raises concerns about revenue growth.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-08-31. EPS is implied from price ÷ P/E. Not investment advice.
Current $50.39
The last 12 months of price, then the range of analyst 12-month targets from today’s $50.39.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Below average on quality vs scored peers
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Raised outlook supports revenue growth objectives.
Advances: Increase annual revenue guidance to $246M-$250M
Q2 beat and guidance raise support revenue growth objective.
Advances: Increase annual revenue guidance to $246M-$250M
Revenue surge supports growth objective and overall thesis.
Advances: Increase annual revenue guidance to $246M-$250M
Increased revenue guidance aligns with growth objectives.
Advances: Increase annual revenue guidance to $246M-$250M
Earnings call details confirm revenue growth.
Advances: Increase annual revenue guidance to $228M-$232M
Earnings beat supports revenue growth objective.
Earnings beat but stock drop indicates market concerns.
